Clinical trial data key to personalization of treatment decisions
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
We push the boundaries of finance to solve complex problems and fuel progress in the world through the MIT finance ecosystem – a unique global network of people, programs, research, and partnerships.
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
By
Generative artificial intelligence can help designers come up with new ideas, according to a new study.
Ahead of the presidential inauguration, MIT Sloan's Professor Andrew Lo and other panelists described advances in their research and how these discoveries are being deployed to benefit the public.
Platform co-founded by a Sloanie taps the wisdom of crowds to label medical data for AI companies.
How does Libra work? How you will be able to use it once it goes live? And what is Calibra doing to address issues around privacy and security?
As decentralized finance projects eliminate the need for financial intermediaries, regulators may need to fundamentally rethink their approach.
The LFE is actively involved in research that aims to identify methods for measuring and managing risk, both standard and systemic types of risk.